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Background: Airway inflammation is a key pathological feature of asthma which underlies its
clinical presentation.
Objectives: To examine whether adding a leukotriene modifier to an inhaled corticosteroid
produces further clinical and/or anti-inflammatory benefits in patients symptomatic on
short-acting b2-agonists.
Methods: Patients uncontrolled on short-acting b2-agonists were treated for 12 weeks with
either fluticasone propionate (100 mcg BD) or fluticasone propionate (100 mcg BD) andn General Hospital, Tremona Road, Southampton SO16 6YD, United Kingdom. Tel.: þ44 2380 794195;
R. Djukanovic).
0 Published by Elsevier Ltd.
1426 R. Djukanovic et al.montelukast (10 mg QD) in a randomized, double-blind, parallel group study. Bronchoscopy
with endobronchial biopsy and bronchoalveolar lavage (BAL) was performed before and after
treatment to compare effects on airway inflammation.
Results: Of 103 subjects enrolled, 89 subjects completed treatment and 82 subjects had
matched pair biopsy samples. Submucosal eosinophil counts, the primary endpoint, and
asthma control improved to similar extents after both treatments (p 0.008). Both treatments
significantly reduced submucosal mast cell, CD3þ, CD4þ, CD8þ and CD25þ cell counts.
Submucosal mast cell reduction was greater in the fluticasone propionate plus montelukast
group. There were no differences between treatments in BAL markers of inflammation or
thickness of sub-epithelial collagen.
Conclusions: Low-dose fluticasone propionate significantly improves clinical disease control
and reduces airway inflammation in asthma patients uncontrolled with short-acting b2-agonists
without further improvement when montelukast is added to low-dose fluticasone propionate.
ª 2010 Published by Elsevier Ltd.Introduction
Airway inflammation and remodelling are believed to
underlie both asthma symptoms and airway hyper-
responsiveness, the hallmark pathophysiological abnor-
mality of this disease. For this reason, anti-inflammatory
treatment is the cornerstone of all asthma management
strategies.1e3 In view of their broad range of anti-inflam-
matory effects,4,5 inhaled corticosteroids (ICS) are recog-
nized as the most effective prophylactic therapy for asthma
and are therefore established as first-line treatment.1e3
However, over the past 20 years, considerable effort has
gone into elucidating the roles of individual mediators,
including histamine, platelet activating factor, prostaglan-
dins, cysteinyl leukotrienes (CysLTs) and, more recently,
cytokines and chemokines. The objective has been to
develop therapies that target key mediator pathways,
thereby providing better asthma control while allowing
reduction of the dose of ICS and reducing side-effects.6,7
Among the mediators studied, CysLTs have been viewed
as possibly being the most important on account of their
broad effects, including bronchoconstriction, vasodilata-
tion, mucus secretion and chemotactic action.8,9 Hence,
CysLT antagonists, in particular leukotriene receptor
antagtonists (LTRAs), are suggested as having the greatest
therapeutic potential, with numerous studies showing
positive clinical effects.10,11 Current guidelines recommend
LTRAs as an alternative treatment added to regular ICS
treatment1,2 in patients not adequately controlled with ICS
alone. While this results in improved symptom control,10,11
the mechanisms of this improvement are unknown. LTRAs
exert effects on several cells involved in the inflammatory
process.12 Potential effects on eosinophils are possibly the
most clinically relevant given the observations that strat-
egies which aim to control asthma symptoms as well as
reduce sputum eosinophilia prevent asthma exacerbations
more effectively than treatments focused solely on
symptom control.13,14 However, it is not known what
additional anti-inflammatory benefits, above and beyond
those of ICS, might be provided by LTRAs.
We report here the findings of a large bronchoscopic
study. We evaluated whether adding the LTRA, montelukast
(MON) 10 mg once daily (QD), to a low dose of the ICS,fluticasone propionate (FP) 100 mcg twice daily (BD), had
additional anti-inflammatory effects in patients with mild
to moderate asthma inadequately controlled with b2-
agonist therapy alone. Airway eosinophils were chosen as
the primary outcome variable of inflammation because they
are a hallmark feature of asthma and because of the
association between the suppression of airway eosinophilia
and better disease control.14,15Methods
Study design and subject characteristics
This randomized, double-blind study (FPD40014) was con-
ducted at 11 centres. Approval of the study was obtained
from local ethics committees and all patients provided
written informed consent. The study compared the anti-
inflammatory and clinical effects of low-dose inhaled FP
(100 mcg BID) with MON (10 mg QD) orally (FPþMON) with
low-dose inhaled FP alone (FP). Before randomization and
after 12 weeks of treatment, endobronchial biopsy and
bronchoalveolar lavage (BAL) were undertaken to assess
treatment effects onairway inflammation (seeFig. 1). During
a 24-day run-in period patients were confirmed as having
mild to moderate asthma with symptoms requiring, as indi-
cated by asthma guidelines,1e3 the introduction of an ICS.
All the patients had asthma for 6 months and used only
short-acting b2-agonists for symptom relief for 6 weeks
before enrollment. Indeed, all of the patients were
required not to have used any ICS for at least 6 weeks prior
to screening, but the protocol did not allow an ICS washout
period prior to randomization. A further requirement was
no use of leukotriene modifiers, cromolyn/nedocromil,
theophylline products, and anticholinergics or combination
products for 6 weeks prior to screening. Study investigators
were expected to follow ICH guidelines for the ethical
treatment of study subjects, and therefore should not have
directed subjects to discontinue ICS (or other asthma
medications) for 6 weeks prior study screening. In summary,
all patients screened for study entry should have been on
their “standard” asthma treatment without recent a recent
change in medication. It is possible that some of the
Figure 1 Study design.
LTM does not enhance or supplement ICS 1427patients in this study never used ICS; however, we did not
collect data that would provide us with that information.
Finally, no use of long-acting or oral beta agonists was
a requirement 48 h prior to the screening visit. Clinic charts
reflected compliance with these conditions but similarly
these data were not collected. After initial screening (Visit
1), any pre-study bronchodilator was replaced with salbu-
tamol two inhalations as needed during the 24-day run-in
period. Patients were not restricted in any way in the use of
rescue medication. Each patient was instructed to use the
study provided short-acting beta agonist for symptom
relief; however there was no prohibition against prophy-
lactic use prior to exercise. No defined symptoms were
required to be observed to justify use of rescue medication.
At Visit 1A (10 to 14 days prior to randomization Visit 2), all
subjects met criteria for disease activity as assessed by
a composite asthma score on a 0e5 point scale for chest
tightness, wheezing, and shortness of breath. Baseline
bronchoscopy and BAL were performed at this visit.
To ensure safety and tolerability of bronchoscopy at Visit 1A
and to proceed to Visit 2 for randomization, subjects were
required to have a pre-salbutamol forced expiratory
volume in one second (FEV1) of >60% of predicted and
within 15% of the highest pre-salbutamol FEV1 obtained
at screening (Visit 1). To fulfill the criteria for treatment
with regular ICS, patients had to use salbutamol on 3 days
and/or report a diary card symptom score of >2 on 3 or
more days during the week preceding the randomization
visit (Visit 2).
Once subjects successfully completed the run-in period
and the baseline bronchial biopsy and BAL procedures and
met all protocol defined eligibility criteria, they were
assigned a unique treatment number as an identification
number for blinded study medication. Treatment numbers
were assigned consecutively as eligible subjects were
randomized. Each site was supplied with open-label FP
DISKUS 100 mcg and blinded MON 10 mg capsules and
matching placebo. At the randomization visit (Visit 2),
eligible subjects were randomized in a 1:1 manner to
receive either inhaled FP DISKUS 100 mcg BID plus oral
placebo QD or inhaled FP DISKUS 100 mcg BD plus oral MON
10 mg QD.
In order to be randomized at Visit 2, subjects had to
fulfill the following criteria: no evidence of respiratory
tract infection for 14 days before Visit 2 and no asthma
exacerbation. At Visits 3, 4 and 5 (4 weeks apart), clinical
indices of asthma control (peak expiratory flow [PEF],salbutamol use, and symptoms), adverse events and asthma
exacerbations were recorded. Subjects who experienced
2 exacerbations, successfully treated with oral cortico-
steroids, continued study treatment for 12 weeks and then
underwent a second bronchoscopy.Airway sampling and analysis of inflammation
Endobronchial biopsy and BAL were conducted at all
centers using the same protocol after centrally coordinated
training. At each bronchoscopy, five or more biopsies were
obtained from either the right middle and lower lobes or
the lingula and left lower lobe. BAL was performed in the
contralateral upper lobe using two 50 mL aliquots of phys-
iological saline. Post-treatment sampling was performed in
equivalent segments of the contralateral lung. Biopsies
were analysed centrally using monoclonal antibodies for
eosinophil cationic protein (ECP), tryptase and T cell
surface markers, and measuring the thickness of the sub-
epithelial collagen reported previously described.16,17
In order to qualify for detailed immunohistochemical
analysis, tissue sections had to contain a minimum of
0.46 mm2 of submucosal tissue (lamina propria), excluding
smooth muscle, glands and crush artifact.18 Immunohisto-
chemical analysis of pre- and post-treatment biopsies for
the numbers of eosinophils, total T cells and CD4þ and
CD8þ T cell subsets, T cells bearing the interleukin-2 (IL-2)
receptor, mast cells and neutrophils was performed as
previously described,16 employing the following monoclonal
antibodies: anti-eosinophil cationic protein (EG2; Diag-
nostic Developments, Uppsala, Sweden) for eosinophils,
anti-tryptase antibody (AA1) for mast cells, anti-neutrophil
elastase (NP57) for neutrophils, anti-CD3 antibody (UCHT1)
for total T cells, MT310 for CD4þ helper cells, DK25 for
CD8þ suppressor/cytotoxic T cells and ACT-1 identifying
activated T cells bearing the interleukin-2 receptor (IL-2R,
CD25; all from DakoCytomation). Positively stained nucle-
ated cells were counted separately in the submucosa and
epithelium as previously reported16 and cell counts
expressed per mm2 of submucosa and per mm length of
intact, longitudinally oriented epithelium. In order to
assess the effect of treatment on collagen deposition, the
thickness of the sub-basement membrane collagen layer,
the lamina reticularis, was measured underneath the
epithelium, also selecting intact, longitudinally orientated
epithelium.
1428 R. Djukanovic et al.Similarly, BAL samples obtained before and after treat-
ment were analysed using standard methods for inflam-
matory cell counts and mediators including ECP, tryptase,
granulocyte macrophage colony stimulating factor
(GM-CSF), and interleukin-8 (IL-8).16e19 Prior to mediator
analysis, samples were concentrated by ultrafiltration
through a 5 kD cutoff filter.
Interleukin-5 (IL-5), IL-8 and GM-CSF were measured
using commercial ELISA kits (R&D Systems, Minneapolis,
MN). Tryptase and ECP were measured using the UniCAP
system (Pharmacia Diagnostics). BAL concentrations were
back-calculated for the degree of ultrafiltration and results
expressed as weight per mL of unconcentrated BAL.
Statistical analyses
Data from previous studies20,21 indicated that 50 subjects
per treatment arm would provide 74% power to ensure
that a 95% confidence interval (CI) for the difference in
eosinophils in the submucosa between treatments was
contained within the margin of equivalence (25%), where
a 50% difference was considered clinically relevant.
Analyses of covariance (ANCOVA) adjusting for center and
baseline were carried out to construct the appropriate CI
for between treatment group difference in each clinical
outcome and each biopsy and BAL variable that did not
violate the assumption of normality based on Shapiro-Wilk
tests. Baseline values were derived from pre-randomiza-
tion assessments and endpoint values were derived from
the final assessments during the double-blind treatment
period. For those biopsy and BAL variables determined to
be non-normally distributed, differences in treatment
group medians and bootstrap confidence intervals were
used to summarise treatment differences. The bootstrap
confidence intervals were based on one thousand samples
(each with replacement) from each treatment group and
the 2.5% and 97.5% percentiles of the resulting sampling
distribution.22 Within-treatment group differences were
evaluated with paired t-tests and Wilcoxon’s signed rank
tests.
Results
Completed patients
Of 144 patients screened, 103 fulfilled the randomization
criteria and underwent baseline bronchoscopy at Visit 1A.
The 103 enrolled and randomized subjects were similar
between treatment groups at baseline (see Table 1) and
all 103 underwent the first bronchoscopy. Eighty-nine
subjects completed the study and 88 underwent the
second bronchoscopy following treatment (nZ 45 for FP
and nZ 43 for FPþMON). Fourteen subjects withdrew
from the study (see Table 1 and Fig. 2); one subject
completed Visit 5 but did not have a second bronchoscopy.
Three subjects on FP and four on FPþMON experienced
exacerbations (defined as worsening asthma requiring
treatment beyond study drug and needing supplemental
salbutamol use); each had only one exacerbation, three
required oral corticosteroids and none withdrew from the
study due to exacerbation.Immunohistochemical analyses
Eighty-two matched pair biopsies of required quality were
analysed for submucosal markers of inflammation (42 for
the FP group and 40 for the FPþMON group). Only 25 paired
samples (14 in the FP and 11 in the FPþMON group) had
sufficiently adequate epithelium for analysis.
Significant within-treatment group reductions from
baseline were observed after treatment for submucosal
eosinophils, the primary endpoint, for both treatments
(p< 0.001), with no between-group difference (1.40; 95%
CI: 6.61, 8.82) (see Fig. 3). There were also significant
(p 0.010) within-treatment group reductions in the
submucosa for mast cells, neutrophils, and CD3þ, CD4þ,
CD8þ and CD25þ cells (see Table 2). With the exception
of mast cells in the submucosa, where a significantly
greater reduction was seen in subjects treated with
FPþMON, no differences between treatment groups
were noted. Both treatments resulted in significant
(p 0.001), and similar, increases in submucosal neutro-
phil counts. Significant decreases were also observed for
most epithelial inflammatory cells in both groups
(p 0.035) but with no between-group differences (see
Table 3).
The median values for thickness of the lamina retic-
ularis changed from 8.21 to 8.49 microns in the FP group,
and from 8.49 to 10.62 microns in the FPþMON groups. The
change in the thickness of the lamina reticularis was
significant in the FP treatment group (pZ 0.049) but not in
the FPþMON group, with no significant difference between
the two treatment groups (0.18; 95% CI: 1.97, 0.985).
This finding has no simple explanation but is intriguing.
There have been many studies demonstrating small changes
in RBM thickening after treatment with inhaled steroids or
ICS/LABA, but also some studies have shown no
change.23e33 Three months would be considered a short
time for changes in RBM, as the positive studies have
usually been of longer duration (generally 6e12 months).
One could speculate that the change in RBM itself could be
due to changes in matrix composition or changes in wall
edema (more likely especially if ICS/LABA). While the
median increase in the FPþMON group of 0.92 mm (nZ 14)
was significant, the median increase in the FP group was
0.74 (nZ 11) was not significant and the 95% confidence
interval for the difference between these changes
contained zero (95% CI: 1.97, 0.99). That is, no significant
difference between the median changes was observed. One
can conclude that this significant finding is of interest and
could be related to treatment, but it must be interpreted
cautiously as the sample size was small, the duration of
treatment was relatively short, and no adjustments were
made for multiple comparisons.BAL analyses
Paired BAL samples were available for analysis for 86 of the
89 subjects who completed the study. Three had missing
cell counts or insufficient BAL recovery. Median relative
eosinophil and neutrophil counts (expressed as
a percentage of total cells) reduced significantly (p< 0.04)
only after FPþMON treatment (0.5% to 0.35% for eosinophils
Table 1 Baseline characteristics and change from baseline of patient-recorded clinical data after 12 weeks of treatment.
FP 100 mcg BID
(nZ 53)
FP 100 mcg BID þ
MON 10 mg QD (nZ 50)
Treatment difference
(95% CI)a
Mean age, years (SD) 29.7 (11.56) 29.4 (8.93) e
Male/female (%) 36/64 54/46 e
Ethnicity (%)
Caucasian 85 78 e
Black 8 18
American Hispanic 6 4
Asian 2 0
Withdrawals, n (%) 8 (15%) 6 (12%) e
Adverse event 0 0
Asthma exacerbation 0 0
Consent withdrawn 2 (4%) 0
Lost to follow up 2 (4%) 3 (6%)
Protocol violation 1 (2%) 1 (2%)
Otherc 3 (6%) 2 (4%)
Morning PEF, L/min (SEM)b ‘
Baseline 413 (13.6) 476 (20.1) 1.4
Mean change 71.37 (12.85)d 70.86 (13.01)d (39.9, 37.1)
Evening PEF, L/min (SEM)b
Baseline 439 (14.55) 499 (20.32) 3.1
Mean change 54.22 (12.53)d 57.05 (11.29)d (33.8, 40.0)
FEV1, % predicted (SEM)
b
Baseline 76.0 (1.64) 77.43 (1.64) 1.06
Mean change 6.12 (1.32)d 6.72 (1.34)d (2.24, 4.36)
FEV1, L (SEM)
b
Baseline 2.86 (0.09) 3.00 (0.10) 0.03
Mean change 0.24 (0.05)d 0.25 (0.05)d (0.11, 0.16)
FVC, L (SEM)b
Baseline 4.07 (0.12) 4.40 (0.15) 0.01
Mean change 0.13 (0.04)d 0.09 (0.06) (0.12, 0.14)
FEV1/FVC, L (SEM)
b
Baseline 0.71 (0.01) 0.69 (0.01) 0.00
Mean change 0.04 (0.01)d 0.04 (0.01)d (0.02, 0.02)
Salbutamol use, puffs/24 h (SEM)b
Baseline 2.55 (0.31) 3.17 (0.50) 0.41
Mean change 2.02 (0.27)d 2.30 (0.55)d (0.09, 0.92)
Percent rescue-free days (SEM)b
Baseline 28.21 (4.51) 25.42 (5.05) 4.78
Mean change 46.37(5.38)d 44.95 (6.22)d (17.59, 8.03)
All data are shown mean and standard error of the mean (SEM), except for age (mean and standard deviation [SD]), gender (%), ethnicity
(%), and withdrawals (n and %).
a Estimate of the difference in mean changes from Baseline to Endpoint; 95% CI for the difference in mean changes based on ANCOVA
adjusted for center and baseline value.
b Analyses based on assumption of normal data.
c Other reasons that were reported for randomized subjects withdrawing from the study were: compliance issues (nZ 2), refused to
undergo bronchoscopy at Visit 6 (nZ 1), insufficient biopsy (nZ 1), and reported pregnancy (nZ 1).
d Statistically significant (p 0.008) within-treatment group change.
LTM does not enhance or supplement ICS 1429and 1.5% to 1.1% for neutrophils), but this reduction was
not significantly different when compared with FP treat-
ment (0.7e0.4% for eosinophils and 1.6e1.2% for neutro-
phils). Lymphocyte and macrophage counts did not change
in either group (see Table 4).The concentrations of IL-8 and GM-CSF were above the
detection limits in nearly all pre-treatment samples and did
not change in either group after treatment. Pre-treatment
BAL concentrations of tryptase, ECP and IL-5 were below
the detection limit of the assays performed in 42%, 67%,
Figure 2 Consort Diagram.
1430 R. Djukanovic et al.and 87% of the samples, respectively. In view of the small
number of evaluable samples for these mediators and
cytokines, it was felt that statistical comparison was not
appropriate.
Physiological and clinical indices
Within-group changes from baseline for each of the physi-
ologic and clinical indices of asthma control improvedFigure 3 Number of Eosinophils in the Submucosa.significantly and were similar for FP and FPþMON groups
(see Table 1). Improvements in morning PEF were observed
at the earliest post-randomization time-point (Week 1) in
the FPþMON group (36.0 L/min) and in the FP group
(29.48 L/min); these improvements continued in each
treatment group over the 12-week treatment period.
A similar pattern was observed for evening PEF. For the
other measures (FEV1, forced vital capacity [FVC], FEV1/
FVC ratio, 24-h salbutamol use and rescue-free days) there
were similar improvements in both groups over the 12
weeks (see Table 1).Discussion
This study shows that, in patients requiring first-line anti-
inflammatory treatment, adding MON to low-dose FP does
not provide greater control of eosinophilic airway inflam-
mation, beyond that seen with FP alone. The study also
suggests that MON provides no additional benefit with
respect to reducing airway T cells that serve as central
orchestrators of allergic inflammation. The only difference
between the two treatments in the assessment of inflam-
matory cell counts or mediators was seen for mast cells
where adding MON to FP resulted in a slightly greater
reduction in submucosal mast cell counts.
This study is in agreement with that of O’Sullivan
et al.,34 who conducted a crossover study in patients with
milder asthma than those in the current study and showed
significant, but similar, decreases in eosinophils and mast
cells with both treatments. As in the current study, clinical
outcomes were similar in patients receiving ICS alone or ICS
and MON, which is consistent with findings reported by
other investigators.35e37
The effects of FP observed in this study are in keeping
with other studies demonstrating anti-inflammatory effects
of ICS, and the clinical improvements following low-dose
ICS in patients with mild to moderate asthma.6,16,38
However, while asthma symptom control is a central
objective in current guidelines, the notion of treating
inflammation as well as clinical symptoms has gained
prominence recently with evidence that targeting bronchial
hyperresponsiveness39 or sputum eosinophil counts14 even
in patients with well-controlled symptoms may provide
further reduction in asthma exacerbations. Furthermore,
one of these studies39 has shown that this approach can
affect airway remodelling, as shown by reduced thickness
of sub-epithelial collagen. With these considerations in
mind, it is justifiable to ask whether more intensive
preventative treatment is needed than is currently advised
for mild to moderate asthma where symptoms are
controlled at levels believed to be acceptable by most
asthma guidelines. While a simple solution to this question
would be to increase the dose of ICS, this approach would
raise concerns about local and systemic side-effects which
are dose-dependent.40 Therefore, combination of an ICS
with a non-steroidal drug seems an attractive alternative,
particularly, in light of the fact that other studies designed
to explore the additive effects, if any, of leukotriene
receptor antagonists (e.g. montelukast) combined with ICS
when compared to an increased dose of ICS in mild to
moderate symptomatic asthma patients, are not conclusive
Table 2 Submucosal counts of mast cells, neutroph and D3þ, CD4þ, CD8þ and CD25þ T lymphocytes before an r 12 weeks of treatment.
Cell FP 100 mcg BID FP 100 mcg BID þ MON 10 mg Q Treatment
Differencec
95% CIc
Baseline, nZ 51 E point, nZ 42 Baseline, nZ 49 Endp nZ 40
Mast cellsa median (IQR) 22.62 16.36e32.43) 1 44d (12.75e23.88) 28.99 (19.35e36.71) 14.11 65e21.07) 9.40 15.83, 2.96
Neutrophilsb median (IQR) 21.43 (7.33e53.04) 6 33e (22.18e81.55) 21.85 (10.53e41.67) 52.90 .51e81.23) 1.70 11.73, 17.14
CD3þ T cellsb median (IQR) 53.39 (29.56e94.77 2 68d (8.46e42.19) 48.12 (18.66e110.10) 16.74 69e27.30) 15.34 53.41, 19.80
CD4þ T cellsb median (IQR) 29.41 (14.89e55.90 40d (4.21e17.02) 24.30 (10.14e6.65) 6.30 72e12.52) 2.30 28.70, 14.14
CD8þ T cellsb median (IQR) 20.59 (10.38e38.32 12d (3.52e16.19) 17.70 (5.92e43.97) 7.96 56e12.38) 2.89 19.06, 10.34
CD25þ T cellsb median (IQR) 0.00 (0.00e1.43) 00d (0.00e0.26) 0.57d (0.00e2.87) 0.00 00e0.00) 0.07 1.63, 0.59
All data (cells/mm2 of submucosa) are shown as median inte uartile range (IQR, 25e75 percentiles).
a Analyses based on assumption of normal data.
b Analyses based on assumption of non-normal data.
c Estimate of the difference in mean or median changes ba ine to endpoint; 95% CI for the difference in mean or median ges.
d Statistically significant (p 0.010) within-treatment g ch es (decreases).
e Statistically significant (p 0.001) within-treatment g ch es (increases).
Table 3 Epithelial counts of mast cells, neutrophils d C þ, CD4þ, CD8þ, CD25þ T lymphocytes before and afte eeks of treatment.
Cell FP 100 mcg BID FP 100 mcg BID þ MON 10 mg Treatment
Differencec
95% CIc
Baseline, nZ 22 ndpoint, nZ 29 Baseline, nZ 21 Endp nZ 28
Mast cellsa median (IQR) 1.46 (0.75e2.86) .00d (0.00e0.67) 1.32 (0.62e2.17) 0.00 0e0.60) 0.99 2.44, 0.46
Neutrophilsb median (IQR) 0.00 (0.00e1.49) 0.76 (0.00e1.81) 0.00 (0.00e0.00) 0.5 0e3.05) 0.00 1.64, 3.18
CD3þ T cellsb median (IQR) 8.05 (2.27e15.85 .76d (0.00e1.64) 5.65 (1.64e11.73) 0.62 0e3.11) 7.31 12.99, 5.21
CD4þ T cellsb median (IQR) 0.82 (0.00e2.50) .00d (0.00e0.00) 0.00 (0.00e1.74) 0.00 0e0.00) 0.28 3.64, 2.47
CD8þ T cellsþ median (IQR) 3.81 (1.94e9.62) .76d (0.00e1.83) 5.58 (0.00e8.87) 0.51 0e1.42) 0.45 7.46, 6.56
CD25þ T cellsb median (IQR) 0.00 (0.00e0.00) 0.00 (0.00e0.00) 0.00 (0.00e0.00) 0.0 0e0.00) 0.00 0.00, 0.00
All data (cells/mm length of tissue) are shown as median in quartile range (IQR, 25e75 percentiles).
a Analyses based on assumption of normal data.
b Analyses based on assumption of non-normal data.
c Estimate of the difference in mean or median changes ba ine to endpoint; 95% CI for the difference in mean or median ges.
d Statistically significant (p 0.035) within-treatment g ch ges (decreases).
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1432 R. Djukanovic et al.with respect to improved lung function or decline in airway
inflammatory markers.41e46 Hence, the objective of this
study was focused on seeing whether justification for
addition of a LT modifier could be found in any residual
pathology, e.g. further reduction in eosinophil counts
which, many studies have shown, are a good indictator of
risk of exacerbation. As shown in Fig. 3, a significant
reduction in residual eosinophilia in the airways post-
treatment did not demonstrate any benefit from adding
MON.
Although the results of our study cannot be extrapolated
to more severe disease, where any residual inflammation
not adequately controlled by ICS could conceivably benefit
from an LTRA, we were unable to show a significant addi-
tional anti-inflammatory effect in mild to moderate disease
when patients respond well clinically to an ICS alone.
This study was powered to elucidate whether MON has
any additional benefits on airway eosinophils. Analysis of
other cell types showed a slightly greater reduction in mast
cell counts as the only observed additional benefit of MON.
The relevance of this finding is unclear, but it could reflect
reduced pro-inflammatory effects of mast cell mediators
and, conceivably, cytokines which mast cells have been
shown to produce.20 In keeping with observations in
numerous in vivo and in vitro studies of corticosteroids on
isolated cells, FP had a pronounced effect on the numbers
of T cells which have long been viewed as key orchestrators
of inflammation. Inhaled corticosteroids not only reduce
the numbers of T cells but also switch off their production
of Th2 cytokines.6,7 To our knowledge, LTRAs have no such
effects which might explain the lack of additional effects
on inflammation.
The two treatments were not different with respect to
effects on the thickness of the lamina reticularis. Given
that this study showed no benefit from either one of the
treatment regimens with respect to collagen deposition and
the fact that this is only one of several measures of airways
remodelling, longer term studies may be necessary to
evaluate the effects of either treatment regimen on
remodelling.
This study showed that both FP and FPþMON treatment
resulted in a significant rise in neutrophil numbers in the
submucosa. The pro-survival effect of corticosteroids on
neutrophils in vitro and the rise in circulating numbers of
neutrophils in vivo seen shortly after introduction of these
drugs47 provide a likely explanation for the increase in
airway neutrophils. However, the relevance of this finding
is unclear and further studies are required to elucidate
whether this is associated with increased neutrophil
activation.
There are potential limitations in this study. First, ICS
act broadly on the inflammatory cascade, including leuko-
triene pathways by which LTRAs exert their pharmacolog-
ical effect; these pathways may have been sufficiently
controlled by ICS alone. Thus the reduction of numbers of
eosinophils, a key source of leukotrienes, could in itself
lead to reduced participation of leukotriene pathway
products. Corticosteroids also have a direct effect at the
cell membrane inhibiting phospholipase A2, which is
a precursor of arachidonic acid. This, in turn, modulates
the pathways of cyclooxygenase and 5-lipoxygenase. Thus,
corticosteroids have an indirect effect on the leukotriene
LTM does not enhance or supplement ICS 1433pathway.On the other hand, 5-lipoxygenase, a key enzyme
in this cascade, is located in the nucleus in some cell types
and in the cytosol of others. Leukotriene modifiers or anti-
leukotrienes constitute 5-lipoxygenase inhibitors and cys-
teinyl leukotriene receptor antagonists (montelukast). The
cysteinyl leukotrienes cause plasma leakage from post-
capillary venules and enhance mucus secretion. LD4 and
another 5-lipoxygenase derived eicosanoid, 5-oxyo-ETE, are
important eosinophil chemoattractants and, subsequently,
in inflammation. However, despite the understanding of
these mechanisms, the direct role of ICS in the leukotriene
pathway is still unclear.48 Thus, inclusion of a third group of
patients treated only with MON may have shown anti-
inflammatory effects of this LTRA alone which may have
provided further clues as to how this drug works.
Second, in this relatively mild population, an initial
positive response to ICS treatment, i.e., reduction in
eosinophil counts, was expected. Hence our question was
whether addition of another anti-inflammatory drug, i.e.
montelukast, could further reduce the cell counts and
provide added benefit. Indeed, the vast majority of
patients improved with respect to both clinical and path-
ological outcomes with FP treatment alone, leaving little
room for further improvement. Thus a beneficial anti-
inflammatory effect of MON could not be excluded in
patients in whom the use of an ICS does not result in such
a marked anti-inflammatory effect. However, as can be
seen in Fig. 3, the reduction in eosinophil counts was
marked but not complete. Thus, we can conclude that
there is no marked benefit of adding montelukast to fluti-
casone in this patient population. Third, the concentrations
of several relevant mediators were below detection limits
in BAL making it difficult to appreciate their relevance in
the patients studied. Finally, sampling of mucosal tissue in
this study was performed only in the proximal airways
accessible by bronchoscopy. Although analysis of BAL,
which samples the distal airway and alveolar compartment
compartments, showed no differences between the two
treatments, it is possible that differential effects might
have occurred in the airways mucosa.
In summary, the results of this study show that adding
MON to low-dose FP does not provide better control of
airway inflammation in patients with asthma requiring first-
line anti-inflammatory treatment. Coupled with the lack of
additional benefit on measured clinical outcomes, the study
suggests that there is little justification for adding MON to
regular low-dose FP as first-line preventative therapy for
asthma.
Funding
Funding for this research was provided by GlaxoSmithKline.
Conflicts of interest
Declaration of all sources of funding: Dr. Djukanovic
reports consultant agreements with and co-founder of
Synairgen; research grants from GlaxoSmithKline and
Novartis; and has provided legal consultation/expert
witness testimony for Synairgen. Dr. Wilson reports
research grants from GlaxoSmithKline. Dr. Moore reportscontractual lab work for GlaxoSmithKline. Dr. Jarjour
reports advisory boards for and honoraria from
GlaxoSmithKline and Genentech; and research grants from
GlaxoSmithKline, Merck & Co., Genentech, MedImmune,
Amgen, University of Nebraska, Roche, Ception Thera-
peutics, Johnson & Johnson, Curalogic AS, Medicinova,
Allergy therapeutics, Wyeth, Greer Laboratories, Inc., and
Schering Plough Corporation. Dr. Koenig reports speaker’s
bureaus for Pfizer, GlaxoSmithKline, and Boehringer-
Ingleheim; and research grants from GlaxoSmithKline.
Dr. Laviolette reports lectures for Merck-Frost; and
research grants from GlaxoSmithKline, Asthma Therapeu-
tics, Merck-Frost, and AstraZeneca. Dr. Bleecker reports
consulting and speaking for AstraZeneca; and clinical
trials research grants through Wake Forest Health
Sciences. Dr. Davis reports no interests to disclose.
Dr. Doherty reports research grants from GlaxoSmithKline,
Novartis, Schering, Intermune, and Boehringer-Ingleheim.
Dr. Olivenstein reports advisory boards and lectures for
GlaxoSmithKline, AstraZeneca, and Novartis. Dr. Israel
reports advisory boards for Merck, Genentech and Teva;
speaker’s bureaus for Merck and Genentech; and research
grants from Genentech, MedImmune and Johnson &
Johnson. Dr. Kavuru reports no interests to disclose.
Dr. Kleerup reports honoraria from Ivax/Teva; and
research grants from GlaxoSmithKline, BIPI, Roche, Ivax/
Teva, MediciNova, Almirall, Novartis, AstraZeneca, Pfizer,
Nabi, Chesi, Osiris, Forest, Genentech, and NIH/NHLBI.
Ms. Reilly, Mr. Yancey, and Dr. Edwards are employees of
GlaxoSmithKline. Drs. Stauffer and Dorinsky were
employees of GlaxoSmithKline at the time of the
study. Dr. Stauffer is currently an employee of Fibrogen.
Dr. Dorinsky is currently an employee of Teva.Acknowledgements
The authors would like to thank Ibrahim Raphiou, PhD for
assistance in preparing the manuscript. The authors also
thank Helen Rigden, MSc and Janet Underwood, BSc for
their assistance with immunohistochemistry and Lynette
Johnson, BS and Annette Hastie, PhD for their assistance
with BALF cytokine analyses and cell counts.
References
1. British Thoracic Society. Scottish Intercollegiate Guidelines
Network. British guideline on the management of asthma.
Thorax 2003;58(Suppl. 1):1le94.
2. GINA Report. Global strategy for asthma management and
prevention, From the global strategy for asthma management
and prevention. Global Initiative for Asthma (GINA). Available
from: http://www.ginasthma.org; 2006.
3. National Asthma Education and Prevention Program. Executive
summary of the NAEEP expert panel report 3: guidelines for
the diagnosis and management of asthma. Bethesda, MD:
National Heart, Lung, and Blood Institute, National Institutes
of Health; June 2007. NIH Publication No. 07-4051.
4. Sousa A, Poston R, Lane S, Nakhosteen J, Lee T. Detection of
GM-CSF in asthmatic bronchial epithelium and decrease by
inhaled corticosteroids. Am Rev Respir Dis 1993;147:1447e61.
5. Sue-Chu M, Wallin A, Wilson S, Ward J, Sandstrom T,
Djukanovic R, et al. Bronchial biopsy study in asthmatics
1434 R. Djukanovic et al.treated with low and high-dose fluticasone propionate (FP)
compared to low-dose FP combined with salmeterol. Eur
Respir J 1999;S30:124.
6. Barnes P. How corticosteroids control inflammation: Quintiles
Prize lecture 2005. Br J Pharmacol 2006;148:245e54.
7. Barnes P. Current issues for establishing inhaled corticosteroids
as the anti-inflammatory agents of choice in asthma. J Allergy
Clin Immunol 1998;101:S427eS433.
8. Calhoun W, Lavins B, Minkwitz M, Evans R, Gleich G, Cohn J.
Effect of zafirlukast (Accolate) on cellular mediators of
inflammation. Am J Respir Crit Care Med 1998;157:1381e9.
9. Hasday J, Meltzer S, Moore W, Wisniewski P, Hebel J, Lanni C,
et al. Anti-inflammatory effects of zileuton in a subpopulation
of allergic asthmatics. Am J Respir Crit Care Med 2000;61:
1229e36.
10. Laviolette M, Malmstrom K, Lu S, Chervinski P, Pujet J, Peszek I,
et al. Montelukast added to inhaled beclomethasone in treat-
ment of asthma. Am J Respir Crit Care Med 1999;160:1862e8.
11. Vaquerizo M, Casan P, Castillo J, Perpina M, Sanchis J,
Sobradillo V, et al. Effect of montelukast added to inhaled
budesonide on control of mild to moderate asthma. Thorax
2003;58:204e10.
12. Drazen J, Israel E, O’Byrne P. Treatment of asthma with drugs
modifying the leukotriene pathway. N Engl J Med 1999;340:
197e206.
13. Green R, Brightling C, McKenna S, Hargadon B, Neale N,
Parker D, et al. Comparison of asthma treatment given in
addition to inhaled corticosteroids on airway inflammation and
responsiveness. Eur Respir J 2006;27:1144e51.
14. Green R, Brightling C, McKenna S, Hargadon B, Parker D,
Bradding P, et al. Asthma exacerbations and sputum eosinophil
counts: a randomized controlled trial. Lancet 2002;360:
1715e21.
15. Pizzichini E, Pizzichini M, Leigh R, Djukanovic R, Strek P. Safety
of sputum induction. Eur Respir J 2002;20(Suppl. 37):9se18s.
16. Jarjour N, Wilson S, Koenig S, Laviolette M, Moore W, Davis W,
et al. Control of airway inflammation maintained at a lower
steroid dose with 100/50 mg of fluticasone propionate/salme-
terol. J Allergy Clin Immunol 2006;118:44e52.
17. Britten KM, Howarth PH, Roche WR. Immunohistochemistry on
resin sections: a comparison of resin embedding techniques for
small mucosal biopsies. Biotech Histochem 1993;68:271e80.
18. Sullivan P, Stephens D, Ansari T, Costello J, Jeffery P. Variation
in measurements of basement membrane thickness and
inflammatory cell number in bronchial biopsies. Eur Resp J
1998;12:811e5.
19. Moore W, Hasday J, Meltzer S, Wisnewski P, White B,
Bleecker E. Subjects with mild and moderate asthma respond
to segmental allergen challenge with similar, reproducible,
allergen specific inflammation. J Allergy Clin Immunol 2001;
108:908e14.
20. Kraft M, Martin R, Lazarus S, Fahy J, Boushey H, Lemanske R,
et al. Airway tissue mast cells in persistent asthma: predicator
of treatment failure when patients discontinue inhaled corti-
costeroids. Chest 2003;124:42e50.
21. Chetta A, Foresi A, Del Donno M, Bertorelli G, Pesci A,
Oliveri D. Airways remodeling is a distinctive feature of asthma
and is related to severity of disease. Chest 1997;111:852e7.
22. Efron B, Tibshirani R. An introduction to the bootstrap. London:
Chapman and Hall; 1993.
23. Ward C. Airway inflammation, basement membrane thickening
and bronchial hyperresponsiveness in asthma. Thorax 2002;57:
309e16.
24. Van den Toorn L. Benefit from anti-inflammatory treatment
during clinical remission of atopic asthma. Respir Med 2005;
99:779e87.
25. Ward C. Inter-relationships between airway inflammation,
reticular basement membrane thickening and bronchialhyper-reactivity to methacholine in asthma; a systematic
bronchoalveolar lavage and airway biopsy analysis. Clin Exp
Allergy 2005;35:1565e71.
26. Capraz F. The effect of inhaled budesonide and formoterol on
bronchial remodeling and HRCT features in young asthmatics.
Lung 2007;185:89e96.
27. Pavord I. Airway inflammation in patients with asthma with
high-fixed or low-fixed plus as-needed budesonide/formoterol.
J Allergy Clin Immunol 2009;123:1083e9.
28. Laitinen A. Tenascin is increased in airway basement
membrane of asthmatics and decreased by an inhaled steroid.
Am J Respir Crit Care Med 1997;156:951e8.
29. Hoshino M. Inhaled corticosteroid reduced lamina reticularis of
the basement by modulation of insulin-like growth factor (IGF)-
I expression in bronchial asthma. Clin Exp Allergy 1998;28:
568e77.
30. Hoshino M. Inhaled corticosteroids decrease subepithelial
collagen deposition by modulation of the balance between
matrix metalloproteinase-9 and tissue inhibitor of metal-
loproteinase-1 expression in asthma. J Allergy Clin Immuol
1999;104:356e63.
31. Orsida B. Effect of a long-acting b2-agonist over three months
on airway wall vascular remodeling in asthma. Am J Respir Crit
Care Med 2001;164:117e21.
32. Boulet L- P. Airway hyperresponsiveness, inflammation, and
subepithelial collagen deposition in recently diagnosed versus
long-standing mild asthma. Am J Respir Crit Care Med 2000;
162:1308e13.
33. Olivieri D. Effect of short-term treatment with low dose
inhaled fluticasone propionate on airway inflammation and
remodeling in mild asthma: a placebo-controlled study. Am J
Respir Crit Care Med 1997;155:1864e71.
34. O’Sullivan S, Akveld M, Burke C, Poulter L. Effects of addi-
tion of montelukast to inhaled fluticasone propionate on
airway inflammation. Am J Repir Crit Care Med 2003;167:
745e50.
35. Leigh R, Vethanayagam D, Yoshida M, Watson R, Rerecich T,
Inman M, et al. Effects of montelukast and budesonide on
airway response and airway inflammation in asthma. Am J
Respir Crit Care Med 2002;166:1212e7.
36. Robinson D, Campbell D, Barnes PJ. Addition of leukotrienes
antagonists to therapy in chronic persistent asthma:
a randomized double-blind placebo-controlled trial. Lancet
2001;357:2007e11.
37. Vignola A. Effects of inhaled corticosteroids, leukotriene
receptor antagonist, or both, plus long-acting beta2-agonist on
asthma pathophysiology: a review of the current evidence.
Drugs 2003;63(Suppl. 2):35e51.
38. Djukanovic R, Wilson J, Britten K, Wilson S, Wall A, Roche W,
et al. Effect of an inhaled corticosteroid on airway inflamma-
tion and symptoms in asthma. Am Rev Respir Dis 1992;145:
669e74.
39. Sont J, Willems L, Bel E, van Kreiken J, Vandenbrouke J,
Sterke P, et al. Clinical Control and histopathologic outcome of
asthma when using airway hyperresponsiveness as an addi-
tional guide to long-term treatment. Am J Respir Crit Care Med
1999;159:1043e51.
40. Ronald N, Bhalla R, Earis J. The local side effects of inhaled
corticosteroids: current understanding and review of the
literature. Chest 2004;126:213e9.
41. Yildrum Z, Ozlu T, Bulbul Y, Bayram H. Addition of montelukast
versus double dose of inhaled budesonide in moderate persis-
tent asthma. Respirology 2004;9:243e8.
42. Perng DW, Huang HY, Lee YC, Perna RP. Leukotriene modifier vs
inhaled corticosteroid in mild to moderate asthma: clinical and
anti-inflammatory effects. Chest 2004;125:1693e9.
43. Barnes N, Laviolette M, Allen D, Flood-Page P, et al. Effects of
montelukast compared to double dose budesonide on airway
LTM does not enhance or supplement ICS 1435inflammation and asthma control. Respir Med 2007;101:
1652e8.
44. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled
glucocorticoids in patients with asthma: systematic review of
current evidence. Br Med J 2002;324:1545e8.
45. Ram FS, Cates CJ, Ducharme FM. Long-acting beta2-agonists
versus anti-leukotrienes as add-on therapy to inhaled cortico-
steroids for chronic asthma. Cochrane Database Syst Rev 2005;
1:CD003137.46. Green RH, Brightling CE, McKenna S, Hargadon B, et al.
Comparison of asthma treatment given in addition to inhaled
corticosteroids on airway inflammation and responsiveness.
Eur Respir J 2006;27:1144e51.
47. Schleimer R. Glucocorticoids supress inflammation but spare
innate immune responses in airway epithelium. Proc Am Thorc
Soc 2004;1:222e30.
48. Funk C, et al. Prostaglandins and leukotrienes: advances in
eicosanoid biology. Science 2001;294:1871e5.
